Jill Lacy MD

Associate Professor of Medicine (Medical Oncology)

Specialties & Subspecialties

Cancer Center, Yale: Brain Tumor Center | Gastrointestinal Cancer Program

Medical Oncology

Education & Training

  • M.D., Yale University (1978)
  • Resident, Yale University School of Medicine , Internal Medicine (1979 - 1982)
  • Fellow, Yale University School of Medicine , Oncology (1982 - 1985)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients

Clinical Interests

Colorectal cancer; pancreatic cancer; esophageal cancer; gastric cancer; gall bladder cancer; anal cancer; biliary cancer; liver cancer; neuroendocrine tumors; brain tumors; non-Hodgkin's lymphoma (NHL); Hodgkin's disease; Kaposi's sarcoma

Cancers Treated

Anal, Brain, Colon (including Rectum), Esophagus, Gall Bladder, Gastrointestinal (including Stomach), Kaposi's Sarcoma, Pancreas, Unknown primary

Board Certifications

  • Internal Medicine, Board Certified (1982)
  • Medical Oncology, Board Certified (1991)

Clinical Trials

ConditionsStudy Title
Colorectal Cancer and ColonA Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer (CALGB 80702)
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Stage IB Esophageal Cancer, Stage IIA Esophageal Cancer, Stage IIB Esophageal Cancer, Stage IIIA Esophageal Cancer, Stage IIIB Esophageal Cancer, and EsophagusRTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma {CIRB}
PancreasPhase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer
Bladder, Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Brain and Nervous SystemA Randomized Phase III open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (GBM)

More Clinical Trials...

Edit Profile